glofitamab
Showing 1 - 23 of 23
Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)
Not yet recruiting
- Large B-cell Lymphoma
- Glofitamab
- +2 more
- (no location specified)
Oct 3, 2023
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)
Not yet recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
- glofitamab
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 18, 2023
Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory Trial (Glofitamab, Pirtobrutinib, Obinutuzumab)
Not yet recruiting
- Mantle Cell Lymphoma
- Mantle Cell Lymphoma Refractory
- Glofitamab
- +3 more
- (no location specified)
Apr 18, 2023
Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)
Not yet recruiting
- Large B-Cell Lymphoma
- Glofitamab
- +5 more
-
Xi'an, ChinaFirst Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023
DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- maplirpacept (PF-07901801)
- +2 more
- (no location specified)
May 30, 2023
Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)
Not yet recruiting
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Glofitamab
- +5 more
-
Boston, Massachusetts
- +1 more
Apr 4, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
- Obinutuzumab
- Glofitamab
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023
Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)
Not yet recruiting
- Mature B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
- (no location specified)
Sep 6, 2022
DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)
Recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Glofitamab
- +6 more
-
Pembroke Pines, Florida
- +3 more
Jan 23, 2023
Lymphoma, Large B-Cell, Diffuse Trial in Austria, Germany (Glofitamab, Rituximab, Obinutuzumab)
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- Glofitamab
- +3 more
-
Linz, Austria
- +17 more
Mar 22, 2023
Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)
Recruiting
- Large B-cell Lymphoma
- mosunetuzumab
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 21, 2022
Lymphoma Trial in Worldwide (Glofitamab, Tocilizumab, Doxorubicin)
Recruiting
- Lymphoma
- Glofitamab
- +6 more
-
Duarte, California
- +13 more
Aug 18, 2022
Non-Hodgkins Lymphoma Trial in Worldwide (Glofitamab, Atezolizumab, Obinutuzumab)
Recruiting
- Non-Hodgkins Lymphoma
- Glofitamab
- +5 more
-
Charlotte, North Carolina
- +21 more
Jan 18, 2023
B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))
Active, not recruiting
- B-Cell Lymphoma
- Non-Hodgkin Lymphoma
- Glofitamab
- +8 more
-
Birmingham, Alabama
- +23 more
Dec 2, 2022
B-cell Lymphoma Trial in Randwick, Clayton, Fitzroy (Glofitamab, Gemcitabine, Oxaliplatin)
Completed
- B-cell Lymphoma
- Glofitamab
- +5 more
-
Randwick, New South Wales, Australia
- +2 more
Nov 23, 2021
Diffuse Large B-cell Lymphoma Trial in Worldwide (Obinutuzumab, Glofitamab, Rituxumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- Obinutuzumab
- +5 more
-
Birmingham, Alabama
- +77 more
Jul 25, 2022